Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence (CRAVR)

November 9, 2021 updated by: Anders Fink-Jensen, MD, DMSci, Psychiatric Centre Rigshospitalet

Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence: A Randomized Controlled Trial (CRAVR)

The study is a single-blinded, randomized, controlled, 12 months clinical trial. The objective is to investigate the feasibility, effects and side-effects of virtual reality-assisted cognitive behavioral therapy (VR-CBT) vs. cognitive behavioral therapy (CBT) in patients with a diagnosis of alcohol dependence.

Study Overview

Detailed Description

Recruitment of participants:

102 patients will be recruited from the Novaví outpatient clinics, where they will be informed orally and in writing about the research project and, if they are interested, an information meeting is booked. If patients show symptoms of abstinence, these are treated prior to the information meeting by doctors and nurses in Novaví. If the patient then wishes to participate and meets the inclusion criteria, informed consent is obtained and screening is performed using the questionnaires described later. Included patients will then be randomized to either:

  1. Virtual reality-assisted cognitive behavioral therapy (VR-CBT)
  2. Cognitive behavioral therapy (CBT) without VR (control group)

Screening:

At the screening sessions, patients' medical history is obtained, as well as their alcohol intake over the past 30 days recorded via Timeline Follow-Back (TLFB). Patients are also asked about previous alcohol dependence treatment and general information about psychosocial factors incl. education, work, marital status, and functional level using Global Assessment of functioning (GAF). In addition, alcohol-related problems are assessed using the Alcohol Users Identification Test (AUDIT), abstinence using the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar), intake of other drugs using the Drug User Identification Test (DUDIT), and alcohol craving using the Penn Alcohol Craving Scale (PACS). The Becks questionnaires, Depression Inventory 2 (BDI-II) and Beck's Anxiety Inventory (BAI), are included to assess the degree of anxiety and depression, and in addition, tests of mental function are performed using the Screening for Cognitive Impairment in Psychiatry (SCIP).

Intervention:

Included participants will in collaboration with their therapist schedule a standard course of treatment based on national guidelines from health authorities. After inclusion, participants are randomized to either:

  1. 14 sessions of VR-CBT (Group A)
  2. 14 sessions of CBT without VR (Group B, control group)

The participants in group A are exposed to VR-simulated high-risk situations filmed in a restaurant, a pub, at home, at a party or at the supermarket, to trigger alcohol cravings and other high-risk induced reactions of which the participants are subsequently trained to handle by trained therapists using CBT-based techniques.

The participants in group B receive the same treatment without VR exposure. The will be 4 weeks of weekly-biweekly treatment, followed by 20-21 weeks of treatment every 2-3 weeks, which is in line with the standard treatment in the Novaví outpatient clinics. The intervention deviates from standard treatment, as none of the participants receive pharmaceutical alcohol treatment during the treatment period (6 months) except for abstinence treatment if needed.

Randomization and blinding:

After screening a patient (ensuring that all inclusion criteria and no exclusion criteria are met) the patient is included. Participants are randomly allocated to either VR-CBT og CBT, 51 participants in each group. Randomization takes place in REDCap, which is a secure web application for building and managing surveys and databases. Age, sex and alcohol consumption are stratified at the time of inclusion ('heavy drinking days' and alcohol consumption - evaluated by TLFB). The technical setup of the randomization tool is performed in close collaboration with an expert in statistics, which ensures correct functionality before starting the experiment. After randomization, the therapist ensures that the participant receives the correct treatment and performs the alcohol craving assessment during each VR-CBT session unblinded using visual analog score (VAS). The study staff conducting the remaining data collections and the entire data analysis remain blinded until the database is opened at the end of the study. In situations where it is necessary to break the blind, it is possible to change the user rights in REDCap and gain access to the randomization tools. With the randomization tools, it is possible to detect the treatment (VR-CBT or CBT) based on study ID and all activities performed in REDCap are registered in the program.

Follow-up:

Each participant must attend a follow-up visit 3, 6, and 12 months from inclusion, where data collection will take place using the before mentioned questionnaires. The follow-up visit will be approx. 1 hour.

Statistical analysis:

All statistical analyzes are performed using the intention-to-treat principle, where all patients who have become randomized and has received a minimum of 1 session of VR-CBT (group A) or CBT without VR (group B), is included in the analysis. Missing data are implemented through the multiple imputation method and the analyzes are performed in the program "R" with alpha = 0.05 and 2-sided test. All continuous effect measures are analyzed using ANOVA from baseline to most recent measurement, and categorical data are analyzed using chi2 analysis. All data distributions will be assessed for normality by visual inspection of histogram and by Q-Q plots. If data is not normally distributed, log transformation is performed, and if this is not successful, non-parametric testing is used.

Study Type

Interventional

Enrollment (Anticipated)

102

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Frederiksberg
      • Copenhagen, Frederiksberg, Denmark, 2000
        • Recruiting
        • Novavi ambulatorierne
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Informed oral and written consent
  • Meets criteria for alcohol dependence syndrome according to International Classification of Diseases (ICD) 10, WHO & Diagnostic and Statistical Manual of Mental Disorder (DSM-5)
  • Age 18 - 70 years old (both included)
  • Minimum 5 'heavy drinking days' in the last month, which is defined as an alcohol intake above 60/48 grams or 5/4 items per. day for resp. men and women over the past 30 days

Exclusion Criteria:

  • Other active substance use defined by DUDIT score> 6 (for men)> 2 (for women) and meet the criteria for other drug dependence according to ICD-10 (excluding nicotine)
  • Does not speak or understand Danish
  • Mental retardation or known severe psychiatric illness or other condition where it is assessed that will interfere with participation eg severely impaired vision or hearing.
  • Medical alcohol treatment (disulfiram, acamprosate, naltrexone or nalmefen) within the latest 4 weeks and during the treatment period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Cognitive Behavioral Therapy (CBT)
CBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
The active comparator receives 14 conventional cognitive behavioral therapy sessions with
Experimental: Virtual Reality Cognitive Behavioral Therapy (VRCBT)
The VR exposure is performed to induce alcohol craving and high-risk induced reactions during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction in total alcohol consumption
Time Frame: Baseline, 6 months, 9 months, 12 months
Percent change in alcohol consumption, defined as "x" grams of alcohol for past 30 days. This will be registered using the Timeline-Follow-Back (TLFB) method.
Baseline, 6 months, 9 months, 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in heavy drinking days
Time Frame: Baseline, 6 months, 9 months, 12 months
Based on the past 30 days of alcohol consumption using time line follow-back (TLFB), heavy drinking days are evaluated. 1 heavy drinking day consists of alcohol consumption exceeding 60/48 grams for men and women respectively.
Baseline, 6 months, 9 months, 12 months
Change in Alcohol Users Identification Test (AUDIT) score
Time Frame: Baseline, 6 months, 9 months, 12 months
Screening for excessive drinking. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Change in Drug User Identification Test (DUDIT) score
Time Frame: Baseline, 6 months, 9 months, 12 months
Identification of individuals with drug-related problems. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Change in Penn Alcohol Craving Scale (PACS) score
Time Frame: Baseline, 6 months, 9 months, 12 months
Assessing alcohol craving. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Screening for Cognitive Impairment in Psychiatry (SCIP) score
Time Frame: Baseline, 6 months, 9 months, 12 months
The 20 minute test is a scale developed for screening cognitive deficits. Higher score = better outcome
Baseline, 6 months, 9 months, 12 months
Change in Global Assessment of functioning (GAF) score
Time Frame: Baseline, 6 months, 9 months, 12 months
GAF measures to what degree a person's symptoms affect their daily functioning on a scale of 0 to 100. Higher score = better outcome
Baseline, 6 months, 9 months, 12 months
Becks Anxiety Inventory (BAI) score
Time Frame: Baseline, 6 months, 9 months, 12 months
Measures the severity of anxiety. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Becks Depression Inventory 2 (BDI-II) score
Time Frame: Baseline, 6 months, 9 months, 12 months
Measures the severity of depression. Higher score = worse outcome
Baseline, 6 months, 9 months, 12 months
Simulator Sickness Questionnaire (SSQ)
Time Frame: Each of the 14 treatment sessions over 6 months
Measures whether participants experience symptoms of simulator sickness while in Virtual Reality. Higher score = worse outcome
Each of the 14 treatment sessions over 6 months
VR-induced craving on a visual analog scale (VAS)
Time Frame: Each of the 14 treatment sessions over 6 months
For each of the 6 VR-scenes, craving is evaluated before, during and after exposure as well as at the end of the therapy session
Each of the 14 treatment sessions over 6 months
Alcohol withdrawal symptoms
Time Frame: Evaluated at inclusion
Alcohol withdrawal symptoms are evaluated at inclusion. Higher score = worse outcome
Evaluated at inclusion
Qualitative assessment
Time Frame: After completion of a full treatment period of 6 months
15 patients and 5 therapists will be asked about advantages and disadvantages of using virtual reality
After completion of a full treatment period of 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 6, 2021

Primary Completion (Anticipated)

March 1, 2024

Study Completion (Anticipated)

March 1, 2024

Study Registration Dates

First Submitted

July 27, 2021

First Submitted That Met QC Criteria

September 10, 2021

First Posted (Actual)

September 13, 2021

Study Record Updates

Last Update Posted (Actual)

November 10, 2021

Last Update Submitted That Met QC Criteria

November 9, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Addiction, Alcohol

Clinical Trials on Virtual Reality Cognitive Behavioral Therapy (CRAVR)

Subscribe